Results 71 to 80 of about 32,890 (266)

The decline of 6‐thioguanine nucleotides is not linked to impaired efficacy or safety of thiopurines in pregnant women with inflammatory bowel disease

British Journal of Clinical Pharmacology, EarlyView.
Background Thiopurines are used to maintain remission in inflammatory bowel disease (IBD). These drugs are metabolized into 6‐thioguanine nucleotides (6‐TGN), associated with efficacy, and 6‐methylmercaptopurine ribonucleotides (6‐MMPR), associated with adverse drug reactions. Pregnancy has been linked to a shift in thiopurine metabolism, characterized
Dianne G. Bouwknegt, Paola Mian, Femke Groen, Denise van den Berg‐Zuiddam, Andrea E. van der Meulen, Femke Crouwel, Nanne K. de Boer, Debbie S. Deben, Dennis R. Wong, Luc J. J. Derijks, Gerard Dijkstra, Arno R. Bourgonje, C. Janneke van der Woude, Marijn C. Visschedijk   +13 more
wiley   +1 more source

A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects

Frontiers in Pharmacology, 2021
Objective: To evaluate the tolerance, variability, and pharmacokinetics (PK) of QX001S, a biosimilar for ustekinumab, in healthy Chinese men.Methods: One hundred and seventy-eight healthy men were recruited in this randomized, double-blind, single-dose ...
Lei Gao, Qingmei Li, Hong Zhang, Min Wu, Min Fang, Lizhi Yang, Xiaojiao Li, Jingrui Liu, Cuiyun Li, Hong Chen, Xiaoxue Zhu, Yanhua Ding, Mingwei Zhou   +12 more
doaj   +1 more source

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. [PDF]

, 2019
BACKGROUND AND AIMS:Treatment pathways for ulcerative colitis (UC) and Crohn's disease (CD) are shifting to a more individualized, risk-stratified approach.
Cao, Charlie, Dulai, Parambir S, Lasch, Karen, Osterman, Mark T, Riaz, Faisal, Sandborn, William J   +5 more
core  

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Clinical Significance of Endoscopic Improvement at 6 Months in Patients With Ulcerative Colitis Treated With Ustekinumab: A Retrospective Real-world Analysis. [PDF]

DEN Open
ABSTRACT Objectives Ustekinumab (UST), an anti‐interleukin‐12/23 p40 monoclonal antibody, has emerged as an effective therapeutic option for patients with moderate to severe ulcerative colitis (UC). However, early predictors of long‐term treatment response remain unclear.
Morikubo H, Matsuura M, Komatsu H, Fujima T, Ogihara R, Oguri N, Mitsui T, Saito D, Hayashida M, Miyoshi J, Hisamatsu T.   +10 more
europepmc   +2 more sources

Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies [PDF]

, 2016
The diverse clinical picture of PsA suggests the need to identify suitable therapies to address the different combinations of clinical manifestations. This review aimed to classify the available biologic agents and new small molecule inhibitors (licensed
Ciurtin, C, Elyoussfi, S, Thomas, BJ
core   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, EarlyView.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis [PDF]

, 2017
This is the peer reviewed version of the following article: F. M. Ali, A. C. Cueva, J. Vyas, A. A. Atwan, M. S. Salek, A. Y. Finlay, and V. Piguet, ‘A systematic review of the use of quality-of-life instruments in randomized controlled trials for ...
Alora-Palli, Asahina, Asawanonda, Augustin, Bagel, Baker, Barker, Basra, Basra, Basra, Beissert, Bergner, Bergstrom, Bernstein, Bishop-Bailey, Bissonnette, Bostoen, Both, Cassano, Chambers, Chen, Choonhakarn, Chren, Crosby, Daudén, Dolan, Drouin, Dubertret, Ellis, Ellis, Ersser, Faurschou, Feldman, Feldman, Feldman, Ferrans, Finlay, Finlay, Finlay, Finlay, Finlay, Finlay, Finlay, Flytström, Fordham, Frendl, Gahalaut, Galvez, Gelfand, Genovese, Gladman, Gniadecki, Goldberg, Gordon, Gordon, Gordon, Gordon, Gottlieb, Gottlieb, Gottlieb, Greenberger, Guida, Gupta, Higgins, Ho, Hutchinson, Igarashi, Jadad, Jensen, Kaltwasser, Katugampola, Kavanaugh, Kerkhof, Kerkhof, Kerkhof, Khilji, Kimball, Kimball, Kimball, Kitchen, Klein, Koek, Koek, Korte, Korte, Korte, Kragballe, Krueger, Krupashankar, Kunynetz, Langley, Langley, Langley, Le Cleach, Lebwohl, Lebwohl, Leonardi, Leonardi, Leonardi, Loo, Lu, Luger, Lui, Lynde, Mamolo, Mattei, McInnes, McKenna, Mease, Mease, Menter, Menter, Menter, Menter, Menter, Menter, Moore, Morgan, Mraz, Möller, Nakagawa, Nash, Nast, Navarini, Norman, O'Brien, Ortonne, Ortonne, Ortonne, Ortonne, Ortonne, Papp, Papp, Papp, Papp, Papp, Papp, Paul, Paul, Piccinelli, Prins, Prinsen, Reich, Reich, Reich, Reich, Reich, Reich, Reich, Revicki, Revicki, Revicki, Roberti, Safikhani, Salek, Salim, Samsa, Saraceno, Saurat, Saurat, Schmitt, Shikiar, Smith, Sofen, Sterry, Strand, Strohal, Tabolli, Terwee, Thaçi, Thaçi, Thaçi, The EuroQol Group, Tiplica, Torii, Tsai, Tsai, Tyring, Tyring, Vedhara, Wall, Ware, Woo, Wright, Yan, Yang, Zachariae, Zheng, Zhu   +188 more
core   +3 more sources

Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST

Alimentary Pharmacology and Therapeutics, 2023
STARDUST, a phase 3b randomised trial, compared ustekinumab therapeutic strategies in patients with Crohn's disease (CD) using early endoscopic assessment and treat‐to‐target (T2T) versus standard of care (SoC).
L. Peyrin-Biroulet, S. Vermeire, Geert D’Haens, J. Panés, A. Dignass, F. Magro, M. Nazar, M. le Bars, Marjolein Lahaye, L. Ni, I. Bravatá, F. Lavie, M. Daperno, Milan Lukáš, A. Armuzzi, M. Löwenberg, D. Gaya, S. Danese   +17 more
semanticscholar   +1 more source

Patient‐ and Clinician‐Related Factors Associated With the Reduction in Opioid Use Among Adults With Chronic Non‐Cancer Pain: A Systematic Review

Clinical Pharmacology &Therapeutics, EarlyView.
Despite known risks, opioids are widely used for chronic non‐cancer pain (CNCP). Clinical guidelines now recommend deprescribing, but factors predicting success are poorly understood. This systematic review aimed to identify clinician and patient factors associated with attaining successful opioid dose reduction or discontinuation in adults with CNCP ...
Alessandra C. Marcelo, Sarah N. Hilmer, David J. Hunter, Stephanie Mathieson, Riyaas Mohamed, Leo Li, Natalie Fung, Anthony Yue, Manuela L. Ferreira   +8 more
wiley   +1 more source